Please assess the completion status of the following clinical trial:

Trial Title: Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. The patient has provided written informed consent with HIPAA authorization.~2. The patient is a candidate for surgical intervention, with lymph node mapping being a part of the surgical plan.~3. The patient is at least 18 years of age at the time of consent.~4. The patient has an ECOG performance status of Grade 0 - 2 (see Appendix A).~5. The patient has a clinical negative node status at the time of study entry (i.e. T0-4, N0, M0, see Appendix D and E).~6. If of childbearing potential, the patient has a negative pregnancy test within 72 hours prior to administration of Lymphoseek, has been surgically sterilized, or has been postmenopausal for at least 1 year.~   Melanoma Patients~7. The patient has a diagnosis of primary melanoma. Breast Cancer Patients~8. The patient has a diagnosis of primary breast cancer.~9. Patients with pure ductal carcinoma in situ (DCIS) or non-invasive carcinoma if lymph node biopsy is part of the surgical plan.~Exclusion Criteria:~1. The patient is pregnant or lactating.~2. The patient has clinical or radiological evidence of metastatic cancer including palpably abnormal or enlarged lymph nodes (i.e., all patients should be any T,N0,M0, see Appendix D and E).~3. The patient has a known hypersensitivity to Lymphazurin.~4. The patient has participated in another investigational drug study within 30 days of scheduled surgery.~   Melanoma Patients~5. The patient has a tumor with a Breslow depth less than 0.75mm.~6. Patient has had preoperative chemotherapy, immunotherapy, or radiation therapy.~7. Patient has been diagnosed with a prior invasive melanoma that would occur on the same body region or potentially draining to the same nodal basin or patients with truncal or extremity primary melanoma who has had a prior breast cancer potentially draining to the same axillary nodal basin.~8. Patient has undergone node basin surgery of any type or radiation to the nodal basin(s) potentially draining the primary melanoma.~9. Patient has undergone a wide excision for their primary melanoma (\>1 cm in dimension) or complex reconstruction (rotation, free flap, or skin graft of any type).~   Breast Cancer Patients~10. The patient has bilateral primary breast cancers or multiple tumors within their breast.~11. Patient has had prior surgical procedures such as breast implants, reduction mammoplasty, or axillary surgery.~12. Patient is scheduled for bilateral mastectomy unless for cosmetic reasons and the contraindicated breast will not undergo lymph node mapping.~13. Patient has had preoperative radiation therapy to the affected breast or axilla.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lymphoseek, Lymphatic mapping, Injection (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete